Vietnam is rapidly strengthening its pharmaceutical manufacturing capabilities, creating significant opportunities for Contract Development and Manufacturing Organisations (CDMOs) and Contract Manufacturing Organisations (CMOs). As pharmaceutical companies diversify supply chains, regionalise production and seek cost-effective manufacturing partners, Vietnam is becoming an increasingly attractive destination for outsourced pharmaceutical development and commercial manufacturing.
Although there is currently no dedicated published valuation for Vietnam's Pharmaceutical Contract Manufacturing market, industry analysis indicates the sector is worth an estimated US$380–480 million in 2025 and could reach US$750 million–1.0 billion by 2030The market is being driven by expanding domestic pharmaceutical production, increasing foreign investment, technology transfer agreements and growing demand for contract manufacturing services across Southeast Asia.
Pharmaceutical contract manufacturers provide outsourced development and production services for pharmaceutical and biotechnology companies, enabling clients to accelerate product development, reduce capital investment and access specialist manufacturing expertise.
The market includes a wide range of services, including:
- Drug product development
- Formulation development
- Active Pharmaceutical Ingredient (API) manufacturing
- Biologics manufacturing
- Sterile injectables
- Oral solid dosage manufacturing
- Packaging and labelling
- Analytical testing
- Technology transfer
- Commercial-scale manufacturing
Vietnam's pharmaceutical industry has entered a period of rapid expansion. Rising healthcare expenditure, an ageing population and increasing demand for medicines are encouraging manufacturers to expand domestic production while reducing dependence on imported pharmaceuticals and ingredients. The government has identified pharmaceutical manufacturing as a strategic industry and continues to encourage technology transfer, local production and investment in advanced manufacturing facilities.
One of the most significant recent developments was the launch of a new vaccine manufacturing facility by Sanofi and Vietnam Vaccine JSC (VNVC). The facility, supported by an investment of approximately US$77 million, is designed to produce 100 million vaccine doses annually and is expected to begin operations by the end of 2027. The partners also signed a technology transfer agreement, highlighting Vietnam's growing capability in advanced pharmaceutical manufacturing.
Vietnam is also benefiting from broader changes in global pharmaceutical supply chains. Pharmaceutical companies are increasingly adopting "China+1" manufacturing strategies, seeking geographically diversified production partners to improve resilience and reduce supply-chain risk. Similar trends have accelerated the growth of CDMO industries across India and Southeast Asia, and Vietnam is well positioned to capture part of this expanding market.
The country's competitive manufacturing costs, improving regulatory framework, skilled workforce and strategic ASEAN location continue to attract international investment. At the same time, domestic pharmaceutical companies are investing in higher-value manufacturing, including biologics, biosimilars, sterile products and active pharmaceutical ingredients.
Technology is also reshaping pharmaceutical manufacturing. Modern CDMOs increasingly utilise continuous manufacturing, process analytical technology (PAT), robotics, artificial intelligence, digital quality management systems and advanced data analytics to improve productivity while meeting increasingly stringent international Good Manufacturing Practice (GMP) requirements.
Globally, pharmaceutical outsourcing continues to accelerate. According to IMARC Group, the Global Pharmaceutical Contract Manufacturing Market is forecast to experience sustained double-digit growth over the coming decade as pharmaceutical companies increasingly outsource development, manufacturing and packaging activities to specialist partners. Demand is particularly strong for biologics manufacturing, sterile injectables, highly potent active pharmaceutical ingredients (HPAPIs), cell and gene therapies and integrated end-to-end CDMO services.
Leading companies operating in the global pharmaceutical contract manufacturing market include Lonza, Catalent, Samsung Biologics, Thermo Fisher Scientific (Patheon), Recipharm, Fareva, WuXi AppTec, WuXi Biologics, Almac Group, Aenova, PCI Pharma Services and Cambrex. These organisations continue to invest in biologics manufacturing, advanced therapies, automation and integrated development capabilities to meet growing global demand.
Vietnam's expanding pharmaceutical manufacturing base, increasing investment in biotechnology, growing API production and supportive industrial policies position the country as one of Southeast Asia's most promising emerging CDMO markets. For pharmaceutical manufacturers, biotechnology companies, equipment suppliers, process technology providers, packaging specialists and international investors, Vietnam offers significant long-term opportunities as regional pharmaceutical production continues to expand.
